NRG-HN004 Newsletter Vol. 2 is Now Posted to the CTSU Website!

A newsletter was just posted for the NRG-HN004 study,  Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with Contraindication to Cisplatin.

This edition of the NRG-HN004 Newsletter includes:

  • an update from the Study Chair, Loren K. Mell, MD
  • accrual and activation news
  • frequently asked questions

 

Read the NRG-HN004 Newsletter on CTSU.org

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
Twitter
Facebook
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse